Quantitative proteomics of pancreatic cyst fluid for early diagnosis of cancer.

Nikitenko, Leonid L.; Manolis, Dimitrios; O'Brien, Darragh P.; Adekeye, Adenike; Kessler, Benedikt M.; Collins, Chris; Kramer, Holger; Chang, David; Maraveyas, Anthony

Abstract

In our EARLY DIAgnosis of PAncreatic Cancer (EARLY DIAPAC) study, we aim to analyse molecular changes or “signatures” associated with early stages of pancreatic carcinogenesis by using the combination of: (i) Label-Free Quantitative Proteomics (LFQP), (ii) Whole Genome Sequencing (WGS) and (iii) High Performance Computer (HPC) VIPER supercomputing capabilities. Building on the large volume of proteomics and genomics work acquired within the field of pancreatic cancer to-date, we focus on exploring the challenging concept of integrating these state-of-the-art platform technologies to conduct molecular analysis of pancreatic cystic fluid (PCyF, as a liquid biopsy) on unprecedented, global, or ‘multi-omics’ (proteogenomics) scale. This innovative approach of characterising PCyF at whole genome and proteome resolution levels in a single diagnostic test would allow for an unbiased profiling of the molecular events associated with early stages of pancreatic carcinogenesis. We have assembled a Multidisciplinary EARLY DIAPAC Consortium across the UK (Hull-Cambridge-Glasgow-Oxford) to conduct multi-omics data analysis of PCyF samples. Proof-of-principle pilot data has been acquired in the first instance. We compared findings from this dataset to confirmed malignant cases and a range of dysplasias to determine the potential of utilising the combination of these state-of-the-art platform technologies for early detection/diagnosis and clinical classification in an area of significant clinical need. Our LFQP and WGS data showed that the differences in PCyF from benign, pre-malignant, and malignant lesions are detectable and quantifiable. Our findings demonstrate that integrative Omics approach has the potential to distinguish molecular “signatures” of PCyF associated with different disease states involving formation of cysts and to advance the field of early detection of pancreatic cancer. The most recent updates from quantitative proteomics part of the EARLY DIAPAC study will be presented at the forum.

Citation

Nikitenko, L. L., Manolis, D., O'Brien, D. P., Adekeye, A., Kessler, B. M., Collins, C., Kramer, H., Chang, D., & Maraveyas, A. Quantitative proteomics of pancreatic cyst fluid for early diagnosis of cancer. Presented at The London Pancreas Workshop 2023, London, United Kingdom

• Presentation Conference Type: Conference Abstract
• Conference Name: The London Pancreas Workshop 2023
• Acceptance Date: Apr 30, 2023
• Online Publication Date: May 31, 2023
• Publication Date: 2023-06
• Deposit Date: Sep 2, 2023
• Journal: Pancreatology
• Print ISSN: 1424-3903
• Electronic ISSN: 1424-3911
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 23
• Issue: 4
• Pages: e7-e8
• DOI: https://doi.org/10.1016/j.pan.2023.04.025
• Keywords: Gastroenterology; Hepatology; Endocrinology, Diabetes and Metabolism
• Public URL: https://hull-repository.worktribe.com/output/4373041
• Publisher URL: https://www.sciencedirect.com/science/article/pii/S1424390323001199
• Additional Information: This article is maintained by: Elsevier; Article Title: Quantitative proteomics of pancreatic cyst fluid for early diagnosis of cancer.; Journal Title: Pancreatology; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.pan.2023.04.025; Content Type: simple-article; Copyright: Copyright © 2023 Published by Elsevier, a division of RELX India, Pvt. Ltd.